ANIP
Income statement / Annual
Last year (2024), ANI Pharmaceuticals, Inc.'s total revenue was $614.38 M,
an increase of 26.20% from the previous year.
In 2024, ANI Pharmaceuticals, Inc.'s net income was -$18.52 M.
See ANI Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$614.38 M |
$486.82 M |
$316.39 M |
$216.14 M |
$208.48 M |
$206.55 M |
$201.58 M |
$176.84 M |
$128.62 M |
$76.32 M |
| Cost of Revenue |
$0.00
|
$181.51 M
|
$138.79 M
|
$100.61 M
|
$87.16 M
|
$63.15 M
|
$73.02 M
|
$79.03 M
|
$48.78 M
|
$12.69 M
|
| Gross Profit |
$614.38 M
|
$305.30 M
|
$177.60 M
|
$115.53 M
|
$121.32 M
|
$143.39 M
|
$128.55 M
|
$97.81 M
|
$79.84 M
|
$63.63 M
|
| Gross Profit Ratio |
1
|
0.63
|
0.56
|
0.54
|
0.58
|
0.69
|
0.64
|
0.55
|
0.62
|
0.83
|
| Research and Development Expenses |
$44.58 M
|
$34.29 M
|
$22.32 M
|
$11.37 M
|
$16.00 M
|
$19.81 M
|
$15.39 M
|
$9.07 M
|
$2.91 M
|
$2.87 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$44.06 M
|
$31.58 M
|
$27.83 M
|
$21.16 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$249.64 M
|
$161.70 M
|
$124.04 M
|
$84.29 M
|
$64.99 M
|
$55.84 M
|
$44.06 M
|
$31.58 M
|
$27.83 M
|
$21.16 M
|
| Other Expenses |
$319.58 M
|
$62.35 M
|
$56.97 M
|
$48.03 M
|
$55.90 M
|
$51.32 M
|
-$550,000.00
|
$55,000.00
|
-$74,000.00
|
$41,000.00
|
| Operating Expenses |
$613.79 M
|
$258.33 M
|
$203.33 M
|
$143.70 M
|
$136.89 M
|
$126.97 M
|
$93.19 M
|
$68.58 M
|
$53.08 M
|
$30.93 M
|
| Cost And Expenses |
$613.79 M
|
$439.85 M
|
$342.12 M
|
$244.31 M
|
$224.05 M
|
$190.12 M
|
$166.22 M
|
$147.61 M
|
$101.86 M
|
$43.62 M
|
| Interest Income |
$0.00
|
$0.00
|
$28.05 M
|
$11.92 M
|
$9.45 M
|
$12.97 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$17.60 M
|
$26.94 M
|
$28.05 M
|
$11.92 M
|
$9.45 M
|
$12.97 M
|
$14.76 M
|
$12.04 M
|
$11.33 M
|
$11.01 M
|
| Depreciation & Amortization |
$67.73 M
|
$59.79 M
|
$56.97 M
|
$47.25 M
|
$44.64 M
|
$44.61 M
|
$33.74 M
|
$27.93 M
|
$22.34 M
|
$6.90 M
|
| EBITDA |
$63.12 M |
$106.60 M |
$48.07 M |
-$1.68 M |
$29.07 M |
$60.74 M |
$69.10 M |
$57.16 M |
$56.31 M |
$39.64 M |
| EBITDA Ratio |
0.1
|
0.22
|
0.1
|
0.07
|
0.14
|
0.29
|
0.34
|
0.32
|
0.38
|
0.52
|
| Operating Income Ratio |
0
|
0.1
|
-0.08
|
-0.15
|
-0.08
|
0.08
|
0.18
|
0.16
|
0.16
|
0.43
|
| Total Other Income/Expenses Net |
-$22.80 M
|
-$27.10 M
|
-$27.38 M
|
-$16.27 M
|
-$9.95 M
|
-$13.19 M
|
-$15.31 M
|
-$11.98 M
|
-$11.40 M
|
-$10.97 M
|
| Income Before Tax |
-$22.21 M
|
$19.87 M
|
-$62.67 M
|
-$56.06 M
|
-$25.96 M
|
$3.16 M
|
$20.05 M
|
$16.35 M
|
$8.68 M
|
$21.73 M
|
| Income Before Tax Ratio |
-0.04
|
0.04
|
-0.2
|
-0.26
|
-0.12
|
0.02
|
0.1
|
0.09
|
0.07
|
0.28
|
| Income Tax Expense |
-$3.69 M
|
$1.09 M
|
-$14.77 M
|
-$13.46 M
|
-$3.41 M
|
-$2.94 M
|
$4.56 M
|
$17.43 M
|
$4.74 M
|
$6.36 M
|
| Net Income |
-$18.52 M
|
$18.78 M
|
-$47.90 M
|
-$42.60 M
|
-$22.55 M
|
$6.09 M
|
$15.49 M
|
-$1.08 M
|
$3.93 M
|
$15.38 M
|
| Net Income Ratio |
-0.03
|
0.04
|
-0.15
|
-0.2
|
-0.11
|
0.03
|
0.08
|
-0.01
|
0.03
|
0.2
|
| EPS |
-0.87 |
0.95 |
-2.95 |
-3.38 |
-1.88 |
0.51 |
1.33 |
-0.0932 |
0.34 |
1.34 |
| EPS Diluted |
-0.87 |
0.94 |
-2.95 |
-3.38 |
-1.88 |
0.5 |
1.32 |
-0.0932 |
0.34 |
1.32 |
| Weighted Average Shares Out |
$19.32 M
|
$18.00 M
|
$16.26 M
|
$12.60 M
|
$11.96 M
|
$11.84 M
|
$11.68 M
|
$11.55 M
|
$11.45 M
|
$11.37 M
|
| Weighted Average Shares Out Diluted |
$19.32 M
|
$18.19 M
|
$16.26 M
|
$12.60 M
|
$11.96 M
|
$12.04 M
|
$11.77 M
|
$11.55 M
|
$11.57 M
|
$11.56 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
